DE602005025998D1 - Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs - Google Patents

Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs

Info

Publication number
DE602005025998D1
DE602005025998D1 DE602005025998T DE602005025998T DE602005025998D1 DE 602005025998 D1 DE602005025998 D1 DE 602005025998D1 DE 602005025998 T DE602005025998 T DE 602005025998T DE 602005025998 T DE602005025998 T DE 602005025998T DE 602005025998 D1 DE602005025998 D1 DE 602005025998D1
Authority
DE
Germany
Prior art keywords
cancer
diagnosis
small cellulose
ghsr1b
ntsr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005025998T
Other languages
English (en)
Inventor
Yusuke Nakamura
Yataro Daigo
Shuichi Nakatsuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of DE602005025998D1 publication Critical patent/DE602005025998D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
DE602005025998T 2004-03-23 2005-03-18 Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs Active DE602005025998D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55578904P 2004-03-23 2004-03-23
PCT/JP2005/005613 WO2005090603A2 (en) 2004-03-23 2005-03-18 Method for diagnosing non-small cell lung cancer

Publications (1)

Publication Number Publication Date
DE602005025998D1 true DE602005025998D1 (de) 2011-03-03

Family

ID=34961862

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005025998T Active DE602005025998D1 (de) 2004-03-23 2005-03-18 Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs

Country Status (9)

Country Link
US (3) US7700573B2 (de)
EP (2) EP1737979B9 (de)
JP (2) JP4938451B2 (de)
CN (1) CN1977052B (de)
AT (1) ATE496142T1 (de)
DE (1) DE602005025998D1 (de)
ES (1) ES2360073T3 (de)
TW (1) TW200600785A (de)
WO (1) WO2005090603A2 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
WO2006090810A2 (en) * 2005-02-25 2006-08-31 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
WO2007013671A2 (en) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
US9347945B2 (en) * 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US20100137163A1 (en) 2006-01-11 2010-06-03 Link Darren R Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors
WO2007097469A1 (en) * 2006-02-24 2007-08-30 Oncotherapy Science, Inc. A dominant negative peptide of imp-3, polynucleotide encoding the same, pharmaceutical composition containing the same, and methods for treating or preventing cancer
EP2018440A1 (de) * 2006-04-20 2009-01-28 Oncotherapy Science, Inc. Nmu-ghsr1b/ntsr1-onkogen-signalweg als therapeutisches ziel bei lungenkrebs
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2530168B1 (de) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Mikrofluidische Vorrichtungen
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
EP2059610A1 (de) * 2006-08-18 2009-05-20 Oncotherapy Science, Inc. Imp-1-onkogen als therapieziel und prognoseindikator für lungenkrebs
JP2010501172A (ja) * 2006-08-25 2010-01-21 オンコセラピー・サイエンス株式会社 肺癌に対する予後マーカーおよび治療標的
EP2845912A1 (de) * 2006-09-12 2015-03-11 Genentech, Inc. Verfahren und Zusammensetzungen zur Diagnose und Behandlung von Lungenkrebs mithilfe des KIT-Gens als genetischem Marker
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
SG183717A1 (en) * 2007-08-20 2012-09-27 Oncotherapy Science Inc Foxm1 peptide and medicinal agent comprising the same
KR20100075858A (ko) * 2007-08-24 2010-07-05 온코세라피 사이언스 가부시키가이샤 암 관련 유전자，ｃｄｃａ５，ｅｐｈａ７，ｓｔｋ３１ 및 ｗｄｈｄ１
CN101855346A (zh) * 2007-08-24 2010-10-06 肿瘤疗法科学股份有限公司 Pkib和naaladl2用作前列腺癌治疗和诊断的靶基因
WO2009028580A1 (en) * 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
EP2060583A1 (de) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identifikation Tumor-assoziierter Marker für Diagnose und Therapie
US9670551B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
CN102899415B (zh) 2007-11-30 2014-12-10 基因特力株式会社 使用膀胱癌特异性甲基化标记基因的膀胱癌诊断试剂盒和芯片
US9797017B2 (en) 2007-11-30 2017-10-24 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9783857B2 (en) 2007-11-30 2017-10-10 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9670552B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US10113203B2 (en) 2007-11-30 2018-10-30 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
ES2584932T3 (es) * 2008-04-16 2016-09-30 Assistance Publique Hôpitaux De Paris Métodos para el tratamiento, la evaluación pronóstica y la estadificación de cáncer no microcítico de pulmón
EP2297581B1 (de) 2008-07-03 2013-04-03 F. Hoffmann-La Roche AG Asc als lungenkrebsmarker
US20110319280A1 (en) * 2008-07-16 2011-12-29 Oncotherapy Science, Inc. Ect2 oncogene as a therapeutic target and prognostic indicator for lung and esophageal cancer
EP2145964A1 (de) * 2008-07-17 2010-01-20 Universität Zu Köln Verfahren zur Früherkennung und Prognose von Lungenkrebs
EP4047367A1 (de) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Verfahren zum nachweis von zielanalyten unter verwendung von tropfenbibliotheken
CA2734979A1 (en) * 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Syngr4 for target genes of cancer therapy and diagnosis
SI2340506T1 (sl) * 2008-09-09 2016-02-29 Somalogic, Inc. Biomarkerji za pljučni rak in njihove uporabe
WO2010037856A2 (en) * 2008-10-03 2010-04-08 Stichting Katholieke Universiteit, Universitair Medisch Centrum St. Radboud DYNACTIN-1/p150glued AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY AND A METHOD FOR IDENTIFYING TARGETABLE DISEASE-RELATED PROTEINS
ES2538002T3 (es) * 2009-01-07 2015-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama
TWI469791B (zh) * 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
ES2703714T3 (es) 2009-03-12 2019-03-12 Cancer Prevention & Cure Ltd Métodos de identificación, evaluación, prevención y terapia de enfermedades pulmonares y kits de los mismos, incluida la identificación, evaluación, prevención y terapia de enfermedades en base al género
EP2411148B1 (de) 2009-03-23 2018-02-21 Raindance Technologies, Inc. Manipulation von mikrofluidiktröpfchen
EP2486409A1 (de) 2009-10-09 2012-08-15 Universite De Strasbourg Markiertes nanomaterial auf siliziumbasis mit verbesserten eigenschaften und seine verwendung
EP2517025B1 (de) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
EP3392349A1 (de) 2010-02-12 2018-10-24 Raindance Technologies, Inc. Digitale analyse von analyten
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
EP3412778A1 (de) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Verfahren zur bildung gemischter tröpfchen
EP3736281A1 (de) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
EP2714970B1 (de) 2011-06-02 2017-04-19 Raindance Technologies, Inc. Enzymquantifizierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
CN105039520A (zh) * 2011-08-03 2015-11-11 西格诺药品有限公司 作为lkb1状态的预测性生物标志物的基因表达谱的鉴定
GB2496150A (en) * 2011-11-02 2013-05-08 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Biomarker and target for responsiveness and resistance to cancer targeting agents
US20130210659A1 (en) 2012-02-10 2013-08-15 Andrew Watson Molecular diagnostic screening assay
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
ES2836127T3 (es) * 2013-03-15 2021-06-24 Sera Prognostics Inc Biomarcadores y métodos para predecir el parto prematuro
JP2014207883A (ja) * 2013-03-27 2014-11-06 国立大学法人岡山大学 がん幹細胞及びその用途
EP2986762B1 (de) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digitale analyse von analyten
TWI643867B (zh) 2013-05-24 2018-12-11 日商腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｉｍｐ－３抗原決定位胜肽及含此之疫苗
JP6689197B2 (ja) * 2013-08-19 2020-04-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト スクリーニング方法
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
EP3090063B1 (de) 2013-12-31 2019-11-06 Bio-Rad Laboratories, Inc. Verfahren zur detektion von latentem retrovirus
EP4353321A2 (de) 2014-08-04 2024-04-17 OncoTherapy Science, Inc. Koc1-abgeleitetes peptid und impfstoff damit
KR20180029046A (ko) 2015-06-19 2018-03-19 세라 프로그노스틱스 인코포레이티드 조산 예측용 바이오마커 쌍
CN105039522A (zh) * 2015-06-24 2015-11-11 湖北工业大学 基于肽核酸探针的Wnt信号通路中FoxM1基因突变的检测试剂、PCR检测方法及应用
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
BR112018005581A2 (pt) 2015-10-08 2018-10-16 Oncotherapy Science, Inc. peptídeo derivado de foxm1 e vacina incluindo o mesmo
JP2019525774A (ja) * 2016-07-19 2019-09-12 ブランダイス ユニバーシティー Ｒｎａ結合ポリペプチドの標的を同定するための組成物および方法
AU2018248293A1 (en) 2017-04-04 2019-10-31 Lung Cancer Proteomics, Llc Plasma based protein profiling for early stage lung cancer prognosis
EP3668996A4 (de) 2017-08-18 2021-04-21 Sera Prognostics, Inc. Clock-schwangerschaftsprotein zur vorhersage des entbindungstermins und der zeit bis zur entbindung
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
CN111317743B (zh) * 2020-03-13 2022-11-29 中国人民解放军第四军医大学 一种基于Kif11基因的重组腺相关病毒抑制病理性疼痛的应用
TWI781647B (zh) * 2020-06-09 2022-10-21 財團法人國家衛生研究院 抗人神經降壓素受體抗體及其用途
CN114561358B (zh) * 2022-03-09 2023-10-03 广州源井生物科技有限公司 一种提高细胞慢病毒感染率的增强感染培养基及方法
CN115478106B (zh) * 2022-08-18 2023-07-07 南方医科大学南方医院 一种基于lr对对三阴性乳腺癌进行分型的方法及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0746609A4 (de) 1991-12-17 1997-12-17 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
EP0823941A4 (de) 1995-04-28 2001-09-19 Abgenix Inc Menschliche antikörper aus xenomäusen
US5889170A (en) * 1997-01-31 1999-03-30 Incyte Pharmaceuticals, Inc. Human integral membrane protein
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6297364B1 (en) * 1998-04-17 2001-10-02 Ludwig Institute For Cancer Research Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
EP1115737A4 (de) * 1998-09-23 2004-11-24 Cleveland Clinic Foundation Durch interferon stimulierte und reprimierte gene
WO2000063353A1 (en) * 1999-04-20 2000-10-26 Cytokinetics Human kinesins and methods of producing and purifying human kinesins
DE19935303A1 (de) * 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US6617115B1 (en) * 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
WO2001094629A2 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US7358353B2 (en) * 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
US6706867B1 (en) * 2000-12-19 2004-03-16 The United States Of America As Represented By The Department Of Health And Human Services DNA array sequence selection
JP2005506298A (ja) * 2001-03-29 2005-03-03 ブリストル−マイヤーズ　スクイブ　カンパニー Ｅｇ５阻害剤を用いる増殖性疾患の治療方法
CA2456334A1 (en) * 2001-08-16 2003-02-27 The United States Of America As Represented By The Secretary Department Of Health And Human Services Molecular characteristics of non-small cell lung cancer
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US7163927B2 (en) * 2002-05-23 2007-01-16 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
EP2213738B1 (de) * 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA moleküle gegen Bcl-2
CN1926551B (zh) * 2003-10-27 2010-06-16 罗斯塔生化科技有限责任公司 用于基因沉默的siRNA的设计方法
AU2005213464A1 (en) * 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer

Also Published As

Publication number Publication date
CN1977052A (zh) 2007-06-06
EP1737979A2 (de) 2007-01-03
WO2005090603A2 (en) 2005-09-29
EP2343384A2 (de) 2011-07-13
US20080050378A1 (en) 2008-02-28
US20100173317A1 (en) 2010-07-08
WO2005090603A3 (en) 2006-03-02
EP2343384A3 (de) 2012-01-04
JP4938451B2 (ja) 2012-05-23
ATE496142T1 (de) 2011-02-15
US20110223687A1 (en) 2011-09-15
TW200600785A (en) 2006-01-01
US7700573B2 (en) 2010-04-20
EP1737979B1 (de) 2011-01-19
ES2360073T3 (es) 2011-05-31
CN1977052B (zh) 2012-09-05
US7972772B2 (en) 2011-07-05
JP2007530006A (ja) 2007-11-01
JP2011039069A (ja) 2011-02-24
EP1737979B9 (de) 2011-09-21

Similar Documents

Publication Publication Date Title
DE602005025998D1 (de) Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs
BRPI0607508B8 (pt) método para detecção e/ou classificação de distúrbios proliferativos celulares colorretais ou hepatocelulares, e uso do mesmo
ATE536420T1 (de) Verbesserte verfahren für beaming
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
WO2005098445A3 (en) Lung cancer biomarkers
WO2006007479A3 (en) Method for enumerating mammalian cell micronuclei via differential staining
WO2004030511A3 (en) Prostate cancer biomarkers
WO2009153775A3 (en) Methods for distinguishing between specific types of lung cancers
WO2006034879A3 (en) Epigenetic methods and nucleic acids for the detection of lung cell proliferative disorders
WO2005085471A3 (de) Verfahren und mittel zur differentiellen diagnose von schilddrüsentumoren
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
ATE426039T1 (de) Verfahren fur den nachweis von streptococcus agalactiae mittels alpha-glucosidase-aktivitat
WO2007118704A3 (en) Methods and nucleic acids for the detection of colorectal cell proliferative disorders
WO2008070144A3 (en) Imprinted genes and disease
ATE403755T1 (de) Identifizierung einer erbb2- genexpressionssignatur bei brustkrebs
DE60321356D1 (de) Verfahren zur diagnostik von eierstock endometriose
MX2010008374A (es) Enriquecimiento en dos etapas de adn fetal libre de celula en plasma materno.
WO2009003706A3 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
WO2005001141A3 (en) Methods and nucleic acids for analyses of colorectal cell proliferative disorders
ATE479778T1 (de) Verfahren zur diagnose nicht-kleinzelliger lungenkarzinome über die trna-dihydrouridin- synthaseaktivität von urlc8
WO2004109286A3 (en) Methods for detecting and treating cancer using podocalyxin and/or endoglycan
WO2004074301A3 (en) Differentially expressed nucleic acids that correlate with ksp expression
ATE494390T1 (de) Verfahren und nukleinsäuren zur analyse von störungen der proliferation von kolonzellen
ATE445592T1 (de) Derivate von heteroarylalkylcarbamaten, verfahren zu deren herstellung und deren verwendung als faah-enzyminhibitoren
WO2004031774A3 (en) Method for treating or preventing metastasis of colorectal cancers